Revolution Medicines, Inc.
NMS: RVMDLive Quote
📈 ZcoreAI Score
Our AI model analyzes Revolution Medicines, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get RVMD Z-Score →About Revolution Medicines, Inc.
Healthcare
Biotechnology
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
📊 Fundamental Analysis
Revolution Medicines, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -58.1%, which indicates that capital utilization is currently under pressure.
At a current price of $96.43, RVMD currently sits at the 69th percentile of its 52-week range (Range: $34.00 - $124.49).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$19.11B
Trailing P/E
--
Forward P/E
-14.32
Beta (5Y)
1.01
52W High
$124.49
52W Low
$34.00
Avg Volume
2.44M
Day High
Day Low